Stock Events

Stock Events

Neuren Pharmaceuticals 

€7.15
0
-€0.15-2.05% Today

Statistics

Day High
7.15
Day Low
7.1
52W High
12.1
52W Low
5.55
Volume
0
Avg. Volume
7
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q4 2025
0.01
0.03
0.05
0.07
Expected EPS
0.007624625715
Actual EPS
0.066870791456

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NK9.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.71B
Acadia Pharmaceuticals targets central nervous system disorders, including rare diseases, similar to Neuren's therapeutic areas.
Biogen
BIIB
Mkt Cap25.38B
Biogen focuses on neurodegenerative diseases, multiple sclerosis, and spinal muscular atrophy, competing in the neurological space with Neuren.
PTC Therapeutics
PTCT
Mkt Cap5.7B
PTC Therapeutics works on rare disorders, including neurological diseases, making it a direct competitor to Neuren.
Ionis Pharmaceuticals
IONS
Mkt Cap12.42B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery for neurological diseases, competing with Neuren's focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals develops RNAi therapeutics for neurological disorders, directly competing with Neuren's research focus.
Anavex Life Sciences
AVXL
Mkt Cap273.38M
Anavex Life Sciences focuses on neurodegenerative and neurological diseases, including Rett syndrome, a key area for Neuren.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is engaged in gene editing for various diseases, including potential treatments for neurological disorders, posing indirect competition to Neuren.

About

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Show more...
CEO
Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), F.C.A.
Employees
8
Country
Other
ISIN
NZNEUE0001S8

Listings

STU
DE
NK9.STU
F
DE
NK9.F
OTC Link
US
NURPF
AU
AU
NEU.AU

0 Comments

Share your thoughts

FAQ

What is Neuren Pharmaceuticals stock price today?▼
The current price of NK9.STU is €7.15 EUR — it has decreased by -2.05% in the past 24 hours. Watch Neuren Pharmaceuticals stock price performance more closely on the chart.
What is Neuren Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Neuren Pharmaceuticals stocks are traded under the ticker NK9.STU.
Is Neuren Pharmaceuticals stock price growing?▼
NK9.STU stock has risen by +1.42% compared to the previous week, the month change is a +2.88% rise, over the last year Neuren Pharmaceuticals has showed a +45.33% increase.
When is the next Neuren Pharmaceuticals earnings date?▼
Neuren Pharmaceuticals is going to release the next earnings report on August 25, 2026.
What were Neuren Pharmaceuticals earnings last quarter?▼
NK9.STU earnings for the last quarter are 0.07 EUR per share, whereas the estimation was 0.01 EUR resulting in a +777.04% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Neuren Pharmaceuticals have?▼
As of April 13, 2026, the company has 8 employees.
In which sector is Neuren Pharmaceuticals located?▼
Neuren Pharmaceuticals operates in the Health & Wellness sector.
When did Neuren Pharmaceuticals complete a stock split?▼
Neuren Pharmaceuticals has not had any recent stock splits.
Where is Neuren Pharmaceuticals headquartered?▼
Neuren Pharmaceuticals is headquartered in Hawthorn East, Other.